Business Context and Reporting Period
This Form 8-K is a current report filed by Cortexyme, Inc. (not Quince Therapeutics, Inc.) on February 16, 2021, covering events as of February 12, 2021. The registrant is a Delaware corporation headquartered in South San Francisco, California, with common stock trading on the Nasdaq Global Select Market under the symbol CRTX.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The report discloses a material event under Item 8.01 (Other Events): On February 15, 2021, Cortexyme issued a press release providing a regulatory update on its development program for Atuzaginstat in the treatment of Alzheimer's Disease. No financial changes or comparative period data are included in this document.
Guidance, Outlook, and Risks
The filing incorporates by reference a press release (Exhibit 99.1) detailing the regulatory status of Atuzaginstat. The document itself does not contain specific management guidance, financial outlook, risk factors, or contingencies beyond the reference to the attached press release.
Investor Verification Checklist
- Verify the company name is Cortexyme, Inc. (CRTX), not Quince Therapeutics, Inc.
- Review the attached Exhibit 99.1 (Press Release dated February 15, 2021) for specific details on the Atuzaginstat regulatory update.
- Consult the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.
- Confirm the current status of the Alzheimer's disease development program via the referenced press release.